The first patient has been recruited to an international trial of a new liver dialysis system, the European Association for the Study of the Liver (EASL) is reporting.
Twenty-four patients will be included in the first-in-man trial to establish the safety and performance of a new device called DIALIVE across seven centres in Europe.
The device was created by scientists and doctors at University College London (UCL) and the Royal Free London NHS Foundation Trust. The hypothesis is that DIALIVE will significantly improve the prognosis of acute on chronic liver failure patients by modulating systemic inflammation.
A second trial that plans to enroll more than 100 patients across Europe is already being designed and is scheduled to begin in 2018. That trial will include patients at another 18 widely distributed European referral hospitals for liver diseases that are part of the European Foundation for the Study of Chronic Liver Failure (EF-Clif) consortium of hospitals.
The trial has been launched at a time when there are more than 1,500 patients on the Eurotransplant waiting list for liver transplant.